Compare Mesoblast Limited (MESO) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Weibo Corp — how do they compare? Mesoblast Limited trades at $16.74 (market cap $2.21B), while Weibo Corp trades at $7.72 (market cap $1.93B). The key difference: Mesoblast Limited and Weibo Corp are close in size by market cap, and Weibo Corp pays a 7.75% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | WB | |
|---|---|---|
Market Cap | $2.21B | $1.93B |
Sector | Technology | Media |
52-Week High | $20.96 | $12.83 |
52-Week Low | $12.88 | $7.20 |
Enterprise Value | $2.21B | $1.20B |
Dividend Yield | — | 7.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.78, up 0.6% with a bullish technical signal from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144% net margin. Recent milestones include Phase 3 trial completion for chronic back pain and BLA filing for heart failure treatment, indicating pipeline progress.
Investment outlook balances promising commercial traction against significant financial losses. The stock offers growth potential from expanding indications but carries high risk due to negative earnings and dependence on regulatory approvals. Analyst consensus leans bullish with 45% buy ratings, though profitability remains the key challenge.
Weibo (WB) trades at $7.76, down 2.82% amid bearish technical signals, though valuation metrics appear attractive with a P/E of 5.5 and P/B of 0.5. The company maintains strong profitability with 21.15% net margins and $449M net income in 2025, but has missed earnings expectations for three consecutive quarters. Cash flow trends show volatility, with 2024 net cash flow negative $694M despite solid operational performance.
The stock presents a value opportunity given deep discount to balance sheet value, but faces competitive pressures and user engagement challenges. Analyst sentiment is mixed with 45% buy ratings, while technical indicators suggest near-term weakness. Key risks include Chinese regulatory environment and competition from Douyin/WeChat.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
